PreOperative Endocrine Therapy for Individualised Care With Abemaciclib
Status:
Recruiting
Trial end date:
2028-09-30
Target enrollment:
Participant gender:
Summary
POETIC-A is a phase 3 trial which targets post-menopausal primary breast cancer patients with
a high 5-year risk of relapse as determined by a high Ki67 after 2 weeks aromatase inhibitor
therapy pre-surgery. Eligible patients will be randomised to standard adjuvant endocrine
therapy alone or standard adjuvant endocrine therapy with a CDK4/6 inhibitor called
abemaciclib.